Nakayama Sohei, Soejima Kenzo, Yasuda Hiroyuki, Yoda Satoshi, Satomi Ryosuke, Ikemura Shinnosuke, Terai Hideki, Sato Takashi, Yamaguchi Norihiro, Hamamoto Junko, Arai Daisuke, Ishioka Kota, Ohgino Keiko, Naoki Katsuhiko, Betsuyaku Tomoko
Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Anticancer Res. 2015 Jan;35(1):261-8.
Clinical microarray datasets were analyzed to search for new therapeutic targets and prognostic markers of non-small cell lung cancer (NSCLC).
Microarray datasets from 90 lung cancer specimens, were analyzed with focus on the FOXD1 gene. Levels of FOXD1 mRNA were assessed in lung cancer cell lines and these levels were correlated with survival.
FOXD1-knockdown led to suppression of cell proliferation. Moreover, patients with high FOXD1 expression survived for a significantly shorter time than those with low FOXD1 expression.
The expression status of FOXD1 is a novel prognostic factor and may lead to new treatment strategies for NSCLC.
分析临床微阵列数据集，以寻找非小细胞肺癌（NSCLC）的新治疗靶点和预后标志物。
分析来自90个肺癌标本的微阵列数据集，重点关注FOXD1基因。评估肺癌细胞系中FOXD1 mRNA的水平，并将这些水平与生存率相关联。
敲低FOXD1导致细胞增殖受到抑制。此外，FOXD1高表达的患者生存时间明显短于FOXD1低表达的患者。
FOXD1的表达状态是一种新的预后因素，可能为NSCLC带来新的治疗策略。
